What is the catalog number for Tiplaxtinin?

The catalog number for Tiplaxtinin is HY-15253.

What sizes are available for Tiplaxtinin?

Tiplaxtinin is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 50 mg, 100 mg.

How many pack sizes does Tiplaxtinin come in?

Tiplaxtinin is available in 5 different pack sizes.

Is Tiplaxtinin in stock?

Tiplaxtinin is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Tiplaxtinin?

Tiplaxtinin is manufactured by QuantiMol.

What is the estimated delivery time for Tiplaxtinin?

Estimated delivery time for Tiplaxtinin is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Tiplaxtinin?

The safety data sheet for Tiplaxtinin is available here: http://file.medchemexpress.com/batch_PDF/HY-15253/Tiplaxtinin-SDS-MedChemExpress.pdf.

Tiplaxtinin

Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM[1].

Product Specifications

CAS Number

393105-53-8

Product Name Alternative

PAI-039; Tiplasinin

UNSPSC

12352005

Hazard Statement

H302+H312, H315, H318, H411

Target

Apoptosis; PAI-1

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Tiplaxtinin.html

Concentration

10mM

Purity

99.03

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(C(O)=O)C1=CN(CC2=CC=CC=C2)C(C1=C3)=CC=C3C4=CC=C(OC(F)(F)F)C=C4

Molecular Formula

C24H16F3NO4

Molecular Weight

439.38

Precautions

H302+H312, H315, H318, H411

References & Citations

[1]Hennan JK, et al. Effect of Tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost. 2008 Sep;6 (9) :1558-64.|[2]Gomes-Giacoia E, et al. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013 Dec;12 (12) :2697-708.|[3]Hennan JK, et al. Evaluation of PAI-039 [{1-benzyl-5-[4- (trifluoromethoxy) phenyl]-1H-indol-3-yl} (oxo) acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 2005 Aug;314 (2) :